Personal information

Verified email domains

Biography

Currently Head of the Clinical Oncology Department at University Hospital and head of the Faculty of Oncology at Jagiellonian University-Medical College, Krakow, Poland. Graduated from the University of Medical Sciences in Poznan, Poland (2000). Ph.D. in molecular biology (2000). Board-certified in medical oncology (2007). Titular professor of medicine (life-time title granted by President of the Republic of Poland - 2012). Scholarships received: Scholarship of the Ministry of Health 2000; Scholarship for Young Scientists founded by “The Politics/POLITYKA” journal; Scholarships of Foundation for Polish Science; Scholarship of American Society for Clinical Oncology – IDEA. Scientific and clinical training – Dept. of Molecular Biology, Roswell Park Cancer Institute Buffalo, NY (1997) and Dept. of Oncology, Princess Margaret Hospital in Toronto, Canada (2008). President of the Polish Society of Clinical Oncology (2015-2019, 2019-2023). During his medical carrier prof. Wysocki was a promoter of four PhDs and trained dozens of medical oncology residents. He is a lead author of national guidelines for the treatment of genitourinary tumors and coauthor of guidelines in breast cancer. Prof. Wysocki serves as an advisor for the Polish Ministry of Health in the process of the development of a national cancer strategy. For the last six years prof. Wysocki has been selected among the top 100 most prominent and influential physicians in Poland. Over the last decade prof. Wysocki established two early-phase clinical study units in Cracow (Jagiellonian University Hospital) and Szczecin (West Pomeranian Cancer Center). Areas of clinical expertise include systemic treatment of breast, gynecologic, and GU cancers and the development of original metronomic chemotherapy-based therapies (chemo-endocrine, chemo-targeted, and metronomic polychemotherapy) for the treatment of advanced, pretreated cancer patients. Scientific interests include the development and application of Immunopheresis for the treatment of solid tumors and the mitigation of immune-related adverse events. Prof. Wysocki has performed first-in-human studies with therapeutic Immunopheresis and developed clinical study protocols for studies on apheresis-based systemic treatment in various solid tumors. Additionally, prof. Wysocki conducts clinical academic studies on the use of unique metronomic chemotherapy regimens as an optional substitution for targeted agents in the situation of their unavailability in low- and middle-income countries. Over the last 15 years prof. Wysocki acted as principal investigator in >70, phase I-III international clinical studies in oncology conducted in Poland. Prof. Wysocki has published >100 peer-reviewed articles on translational, clinical, and preclinical cancer research (ORCID ID: 0000-0003-4003-5278). His educational activities involve lectures and online courses for oncologists, residents and medical students (Jagiellonian University, Poznan University of Medicine). His portfolio comprises >1000 lectures and presentations given during national and international meetings, webinars, and symposia over the last 20 years.

Activities

Employment (2)

University Hospital: Krakow, PL

2016-09-01 to present | Head of Department (Department of Oncology)
Employment
Source: Self-asserted source
Piotr Wysocki

Jagiellonian University - Medical College: Krakow, PL

2016-09-01 to present | Head of Department. Professor of Medicine - Clinical Oncology (Department of Oncology)
Employment
Source: Self-asserted source
Piotr Wysocki

Professional activities (3)

American Association for Cancer Research: Philadelphia, PA, US

2021-01-01 to present | full member
Membership
Source: Self-asserted source
Piotr Wysocki

American Society of Clinical Oncology: Alexandria, VA, US

2008-06-01 to present
Membership
Source: Self-asserted source
Piotr Wysocki

Polish Society of Clinical Oncology: Warsaw, PL

2015-09-01 to 2023-08-31 | President
Service
Source: Self-asserted source
Piotr Wysocki

Works (50 of 105)

Items per page:
Page 1 of 3

Neoadjuvant Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Chemotherapy for Muscle-Invasive Urothelial Cancer: Large, Single-Center Analysis of Consecutive Patients’ Data

Cancers
2025-01-14 | Journal article
Contributors: Łukasz Kwinta; Kamil Konopka; Krzysztof Okoń; Mateusz Łobacz; Piotr Chłosta; Przemysław Dudek; Anna Buda-Nowak; Paweł Potocki; Piotr J. Wysocki
Source: check_circle
Crossref

Strikingly high activity of metronomic chemotherapy in a patient with locally advanced, life-threatening cutaneous squamous-cell cancer — case report and discussion of the literature

Oncology in Clinical Practice
2023 | Journal article
Part of ISSN: 2450-6478
Contributors: Łukasz Kwinta; Piotr J. Wysocki
Source: Self-asserted source
Piotr Wysocki

The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting—A Nation-Wide Retrospective Analysis (RACER)

Cancers
2023-09 | Journal article | Author
Contributors: Paweł Potocki; Rafał Wiśniowski; Dominik Haus; Zbyszko Chowaniec; Maciej Kozaczka; Magdalena Kustra; Marzenna Samborska-Plewicka; Marcin Szweda; Danuta Starzyczny-Słota; Magdalena Michalik et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

Clinical Characterization of Targetable Mutations (BRAF V600E and KRAS G12C) in Advanced Colorectal Cancer—A Nation-Wide Study

International Journal of Molecular Sciences
2023-05-22 | Journal article
Contributors: Paweł M. Potocki; Piotr Wójcik; Łukasz Chmura; Bartłomiej Goc; Marcin Fedewicz; Zofia Bielańska; Jakub Swadźba; Kamil Konopka; Łukasz Kwinta; Piotr J. Wysocki
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma—A network meta-analysis. Focus on cabozantinib combined with nivolumab

Frontiers in Pharmacology
2023-03-03 | Journal article
Part of ISSN: 1663-9812
Contributors: Maciej Niewada; Tomasz Macioch; Magdalena Konarska; Aneta Mela; Adam Goszczyński; Bogusława Przekopińska; Karolina Rajkiewicz; Piotr Wysocki; Maciej Krzakowski
Source: Self-asserted source
Piotr Wysocki

Metronomic Chemo-Endocrine Therapy (FulVEC) as a Salvage Treatment for Patients with Advanced, Treatment-Refractory ER+/HER2-Breast Cancer—A Retrospective Analysis of Consecutive Patients Data

Journal of Clinical Medicine
2023-02-08 | Journal article
Contributors: Anna Buda-Nowak; Łukasz Kwinta; Paweł Potocki; Anna Michałowska-Kaczmarczyk; Agnieszka Słowik; Kamil Konopka; Joanna Streb; Maciej Koniewski; Piotr J. Wysocki
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer

Cancers
2023-02-07 | Journal article
Contributors: Piotr J. Wysocki; Mateusz Łobacz; Paweł Potocki; Łukasz Kwinta; Anna Michałowska-Kaczmarczyk; Agnieszka Słowik; Kamil Konopka; Anna Buda-Nowak
Source: check_circle
Crossref

Badania kontrolne po leczeniu najczęstszych nowotworów litych u dorosłych : zalecenia panelu ekspertów

Nowotwory
2022 | Journal article
URI:

https://journals.viamedica.pl/biuletyn_pto/article/view/93204

Contributors: Jacek Jassem; Anna Kowalczyk; Aleks; er Biesiada; Renata Duchnowska; Rafał Dziadziuszko; Agnieszka Masztalerz-Migas; Andrzej Kawecki; Maciej Krzakowski; Piotr Potemski et al.
Source: Self-asserted source
Piotr Wysocki

Consensus on methods of development of clinical practice guidelines in oncology under the auspices of Maria Sklodowska-Curie National Research Institute of Oncology and the Agency for Health Technology Assessment and Tariff System

Nowotwory Journal of Oncology
2022 | Journal article
Contributors: Jan Walewski; Dominik Dziurda; Mariusz Bidziński; Barbara Bobek-Bilewicz; Marek Dedecjus; Iwona Hus; Beata Jagielska; Jacek Jassem; Andrzej Kawecki; Dariusz Kowalski et al.
Source: Self-asserted source
Piotr Wysocki

Efficacy and safety of lipegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in breast cancer patients in Poland

Archives of Medical Science
2022 | Journal article
Contributors: Joanna Streb; Jakub Kucharz; Aurelia Lipa; Marcin Strzondała; Piotr J. Wysocki
Source: Self-asserted source
Piotr Wysocki

Post-treatment follow-up in common solid malignancies : expert panel recommendations

Nowotwory Journal of Oncology
2022 | Journal article
Contributors: Jacek Jassem; Anna Kowalczyk; Aleks; er Biesiada; Renata Duchnowska; Rafał Dziadziuszko; Agnieszka Masztalerz-Migas; Andrzej Kawecki; Maciej Krzakowski; Piotr Potemski et al.
Source: Self-asserted source
Piotr Wysocki

Expert recommendations on diagnostic-therapeutic management of melanoma patients

Oncology in Clinical Practice
2022-12-21 | Journal article
Part of ISSN: 2450-6478
Part of ISSN: 2450-1654
Contributors: Piotr Rutkowski; Piotr J. Wysocki; Katarzyna Kozak; Anna Nasierowska-Guttmejer; Arkadiusz Jeziorski; Wojciech M. Wysocki; Ewa Kalinka; Tomasz Świtaj; Grażyna Kamińska-Winciorek; Anna M. Czarnecka et al.
Source: Self-asserted source
Piotr Wysocki

Non-resective treatment of pineoblastoma in adult: a case report

Acta Neurologica Belgica
2022-07-29 | Journal article
Part of ISSN: 0300-9009
Part of ISSN: 2240-2993
Contributors: Piotr Wysocki
Source: Self-asserted source
Piotr Wysocki

Metronomic Chemotherapy in Prostate Cancer

Journal of Clinical Medicine
2022-05-18 | Journal article
Contributors: Piotr J. Wysocki; Maciej T. Lubas; Malgorzata L. Wysocka
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Evolution of prostate cancer therapy. Part 1

Oncology in Clinical Practice
2022-03-30 | Journal article
Part of ISSN: 2450-6478
Part of ISSN: 2450-1654
Contributors: Paweł M. Potocki; Piotr J. Wysocki
Source: Self-asserted source
Piotr Wysocki

Reduction of Cancer-Induced Thrombocytosis as a Biomarker of Improved Outcomes in Advanced Gastric Cancer

Journal of Clinical Medicine
2022-02 | Journal article | Author
Contributors: Kamil Konopka; Paulina Frączek; Maciej Lubaś; Agnieszka Micek; Łukasz Kwinta; Joanna Streb; Paweł Potocki; Piotr Wysocki
Source: check_circle
Multidisciplinary Digital Publishing Institute
grade
Preferred source (of 2)‎

Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial

Nature Medicine
2022-01 | Journal article
Part of ISSN: 1078-8956
Part of ISSN: 1546-170X
Source: Self-asserted source
Piotr Wysocki
grade
Preferred source (of 3)‎

Primary bilateral angiosarcoma of the breast treated with neoadjuvant chemotherapy combined with propranolol

The Breast Journal
2021-10 | Journal article
Part of ISSN: 1075-122X
Part of ISSN: 1524-4741
Source: Self-asserted source
Piotr Wysocki

Combined Neutrophil-to-Lymphocyte and Platelet-Volume-to-Platelet Ratio (NLR and PVPR Score) Represents a Novel Prognostic Factor in Advanced Gastric Cancer Patients

Journal of Clinical Medicine
2021-08-30 | Journal article
Part of ISSN: 2077-0383
Source: Self-asserted source
Piotr Wysocki
grade
Preferred source (of 3)‎

Postęp w zakresie leczenia systemowego raka jelita grubego

Oncology in Clinical Practice
2021-07-15 | Journal article
Part of ISSN: 2450-6478
Part of ISSN: 2450-1654
Contributors: Piotr J. Wysocki
Source: Self-asserted source
Piotr Wysocki
grade
Preferred source (of 2)‎

Polish Society of Clinical Oncology and Polish Urological Association Guidelines for the diagnosis and treatment of renal cell cancer

Oncology in Clinical Practice
2021-01-12 | Journal article
Part of ISSN: 2450-6478
Part of ISSN: 2450-1654
Contributors: Piotr J. Wysocki; Piotr Chłosta; Robert Chrzan; Anna Czech; Katarzyna Gronostaj; Kamil Konopka; Maciej Krzakowski; Jakub Kucharz; Krzysztof Małecki; Mikołaj Przydacz et al.
Source: Self-asserted source
Piotr Wysocki

Anemia in cancer patients — Expert Group recommendations. Revision 2020

Oncology in Clinical Practice
2020-10-29 | Journal article
Part of ISSN: 2450-6478
Part of ISSN: 2450-1654
Contributors: Piotr Radziwon; Maciej Krzakowski; Ewa Kalinka; Renata Zaucha; Piotr Wysocki; Dariusz Kowalski; Jerzy Gryglewicz; Marek Z. Wojtukiewicz
Source: Self-asserted source
Piotr Wysocki

Breast cancer - national guidelines

Oncology in Clinical Practice
2020-10-29 | Journal article
Contributors: Piotr Wysocki
Source: Self-asserted source
Piotr Wysocki

European practice patterns and barriers to smoking cessation after a cancer diagnosis in the setting of curative versus palliative cancer treatment.

European journal of cancer (Oxford, England : 1990)
2020-08-29 | Journal article
Source: Self-asserted source
Piotr Wysocki

Preoperative treatment of HER2-positive breast cancer

Oncology in Clinical Practice
2020-05-15 | Journal article
Part of ISSN: 2450-6478
Part of ISSN: 2450-1654
Contributors: Piotr J Wysocki; Maciej Krzakowski
Source: Self-asserted source
Piotr Wysocki

Systemic Treatment of Cancer Patients during SARS-CoV-2 Pandemic

Cancer Therapy & Oncology International Journal
2020-04-22 | Journal article
Part of ISSN: 2473-554X
Contributors: Piotr Wysocki
Source: Self-asserted source
Piotr Wysocki

Retrospective analysis of the efficacy and safety of cabazitaxel treatment in castration-resistant prostate cancer after docetaxel failure

Oncology in Clinical Practice
2020-01-10 | Journal article
Part of ISSN: 2450-6478
Part of ISSN: 2450-1654
Contributors: Jakub Żołnierek; Wojciech Poborski; Wojciech Rogowski; Bogumiła Arłukowicz-Czartoryska; Karolina Skalska; Małgorzata Gola; Jakub Kucharz; Piotr J. Wysocki
Source: Self-asserted source
Piotr Wysocki

Clinical practice of renal cell carcinoma treatment with nivolumab

Oncology in Clinical Practice
2019-10-29 | Journal article
Part of ISSN: 2450-6478
Part of ISSN: 2450-1654
Contributors: Paweł M Potocki; Piotr J Wysocki
Source: Self-asserted source
Piotr Wysocki

Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project

Advances in Therapy
2018 | Journal article
EID:

2-s2.0-85058846827

Contributors: Cazzaniga, M.E.; Munzone, E.; Bocci, G.; Afonso, N.; Gomez, P.; Langkjer, S.; Petru, E.; Pivot, X.; Sánchez Rovira, P.; Wysocki, P. et al.
Source: Self-asserted source
Piotr Wysocki via Scopus - Elsevier

Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor–Targeted Agents

Clinical Genitourinary Cancer
2018 | Journal article
EID:

2-s2.0-85043511442

Contributors: Angelergues, A.; Efstathiou, E.; Gyftaki, R.; Wysocki, P.J.; Lainez, N.; Gonzalez, I.; Castellano, D.E.; Ozguroglu, M.; Carbonero, I.G.; Flechon, A. et al.
Source: Self-asserted source
Piotr Wysocki via Scopus - Elsevier

Polish Society of Clinical Oncology position statement on the urgent need of introduction of national standards for utilization of biologic drugs,Stanowisko Polskiego Towarzystwa Onkologii Klinicznej w sprawie wprowadzenia krajowych standardów stosowania leków biologicznych

Hematologia
2017 | Journal article
EID:

2-s2.0-85042479874

Contributors: Wysocki, P.J.; Krzakowski, M.; Walewski, J.; Duszyńska, M.; Wojtukiewicz, M.Z.; Kowalski, D.; Zyśk, R.
Source: Self-asserted source
Piotr Wysocki via Scopus - Elsevier

Bowel or ovarian cancer? Ambiguous diagnosis and non-standard treatment with good outcomes. A case report,Rak jelita czy rak jajnika? Niejednoznaczne rozpoznanie i niestandardowe leczenie z dobrym efektem. Studium przypadku

Current Gynecologic Oncology
2016 | Journal article
EID:

2-s2.0-85013628711

Contributors: Cybulska-Stopa, B.; Koper, K.; Streb, J.; Wysocki, P.J.
Source: Self-asserted source
Piotr Wysocki via Scopus - Elsevier

Cutaneous melanoma - Guidelines for diagnostics and therapy in 2016,Czerniaki skóry - zasady postêpowania diagnostyczno-terapeutycznego w 2016 roku

Przeglad Dermatologiczny
2016 | Journal article
EID:

2-s2.0-84959263896

Contributors: Rutkowski, P.; Wysocki, P.J.; Nasierowska-Guttmejer, A.; Fijuth, J.; Kalinka-Warzocha, E.; ͆witaj, T.; Jeziorski, A.; Szacht, M.; Zegarski, W.; Wysocki, W.M. et al.
Source: Self-asserted source
Piotr Wysocki via Scopus - Elsevier

Guidelines for the prevention and treatment of venous thromboembolism in non-surgically treated cancer patients

Nowotwory
2016 | Journal article
EID:

2-s2.0-85007079695

Contributors: Wojtukiewicz, M.Z.; Sierko, E.; Tomkowski, W.; Zawilska, K.; Undas, A.; Podolak-Dawidziak, M.; Wysocki, P.; Krzakowski, M.; Warzocha, K.; Windyga, J.
Source: Self-asserted source
Piotr Wysocki via Scopus - Elsevier

Guidelines for the prevention and treatment of venous thromboembolism in patients with cancers treated conservatively,Wytyczne dotyczace profilaktyki i leczenia zylnej choroby zakrzepowo-zatorowej u chorych na nowotwory poddawanych leczeniu zachowawczemu

Hematologia
2016 | Journal article
EID:

2-s2.0-85010788221

Contributors: Wojtukiewicz, M.Z.; Sierko, E.; Tomkowski, W.; Zawilska, K.; Undas, A.; Podolak-Dawidziak, M.; Wysocki, P.; Krzakowski, M.; Warzocha, K.; Windyga, J.
Source: Self-asserted source
Piotr Wysocki via Scopus - Elsevier

Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients

Oncotarget
2016 | Journal article
EID:

2-s2.0-85017070299

Contributors: Duchnowska, R.; Wysocki, P.J.; Korski, K.; Czartoryska-Arłukowicz, B.; Niwińska, A.; Orlikowska, M.; Radecka, B.; Studziński, M.; Demlova, R.; Ziółkowska, B. et al.
Source: Self-asserted source
Piotr Wysocki via Scopus - Elsevier

Intensive anticancer therapy in elderly patients - Does it make sense? A case report,Intensywne leczenie onkologiczne u starszych chorych - Czy to ma sens? Analiza przypadku

Current Gynecologic Oncology
2016 | Journal article
EID:

2-s2.0-85013640778

Contributors: Cybulska-Stopa, B.; Streb, J.; Koper, K.; Wysocki, P.J.
Source: Self-asserted source
Piotr Wysocki via Scopus - Elsevier

Liposomal doxorubicin in patients with breast cancer and concomitant cardiovascular diseases-interdisciplinary expert opinion

Kardiologia Polska
2016 | Journal article
EID:

2-s2.0-84988850542

Contributors: Szmit, S.; Filipiak, K.J.; Litwiniuk, M.; Opolski, G.; Wysocki, P.; Zaborska, B.; Krzakowski, M.
Source: Self-asserted source
Piotr Wysocki via Scopus - Elsevier

The role of neoadjuvant chemotherapy in the management of advanced ovarian cancer in geriatric patients,Znaczenie neoadiuwantowej chemioterapii w leczeniu zaawansowanego raka jajnika u chorych geriatrycznych

Current Gynecologic Oncology
2016 | Journal article
EID:

2-s2.0-85019199738

Contributors: Kojs-Pasińska, E.; Cybulska-Stopa, B.; Koper, K.; Dziobek, K.; Dziechciowski, M.; Chamier-Ciemińska, A.; Streb, J.; Wysocki, P.J.; Wicherek, Ł.
Source: Self-asserted source
Piotr Wysocki via Scopus - Elsevier

Venous thromboembolism prophylaxis in cancer patients — guidelines focus on surgical patients

Acta Angiologica
2016 | Journal article
EID:

2-s2.0-85012225978

Contributors: Urbanek, T.; Krasiński, Z.; Kostrubiec, M.; Sydor, W.; Wysocki, P.; Antoniewicz, A.; Begier-Krasińska, B.; Dyszkiewicz, W.; Kulig, J.; Ładziński, P. et al.
Source: Self-asserted source
Piotr Wysocki via Scopus - Elsevier

Cellular vaccines modified with hyper IL6 or hyper IL11 combined with docetaxel in an orthotopic prostate cancer model

Anticancer Research
2015 | Journal article
EID:

2-s2.0-84931369800

Contributors: Mackiewicz, J.; Kazimierczak, U.; Kotlarski, M.; Dondajewska, E.; Kozłowska, A.; Kwiatkowska, E.; Nowicka-Kotlarska, A.; Dams-Kozłowska, H.; Wysocki, P.J.; Mackiewicz, A.
Source: Self-asserted source
Piotr Wysocki via Scopus - Elsevier

Clinical nutrition in oncology: Polish recommendations,Standardy leczenia zywieniowego w onkologii

Nowotwory
2015 | Journal article
EID:

2-s2.0-84944730095

Contributors: Kłek, S.; Jankowski, M.; Kruszewski, W.J.; Fijuth, J.; Kapała, A.; Kabata, P.; Wysocki, P.; Krzakowski, M.; Rutkowski, P.
Source: Self-asserted source
Piotr Wysocki via Scopus - Elsevier

Recommendations for diagnosis and therapy of cutaneous melanoma,Czerniaki skóry \- zasady postępowania diagnostyczno-terapeutycznego w 2016 roku

Nowotwory
2015 | Journal article
EID:

2-s2.0-84957873861

Contributors: Rutkowski, P.; Wysocki, P.J.; Nasierowska-Guttmejer, A.; Fijuth, J.; Kalinka-Warzocha, E.; ͆witaj, T.; Jeziorski, A.; Szacht, M.; Zegarski, W.; Wysocki, W.M. et al.
Source: Self-asserted source
Piotr Wysocki via Scopus - Elsevier

The outcomes of Polish patients with advanced BRAFpositive melanoma treated with vemurafenib in a safety clinical trial

Wspolczesna Onkologia
2015 | Journal article
EID:

2-s2.0-84942573072

Contributors: Rutkowski, P.; Kozak, K.; Mackiewicz, J.; Krzemieniecki, K.; Nawrocki, S.; Wasilewska-Tes̈luk, E.; Kwinta, Ł.; Wysocki, P.; Koseła-Paterczyk, H.; ͆witaj, T.
Source: Self-asserted source
Piotr Wysocki via Scopus - Elsevier

Polish clinical practice guideline on hyperthermic intraperitoneal chemotherapy (HIPEC) with cytoreductive surgery in peritoneal malignancy treatment,Zasady stosowania dootrzewnowej chemioterapii w hipertermii (HIPEC) w leczeniu nowotworów złos̈liwych powierzchni otrzewnej w połączeniu z zabiegami cytoredukcyjnymi: Zalecenia krajowe

Current Gynecologic Oncology
2014 | Journal article
EID:

2-s2.0-84935071498

Contributors: Rutkowski, P.; ͆piewankiewicz, B.; Herman, K.; Jastrzębski, T.; Kładny, J.; Kojs, Z.; Krzakowski, M.; Polkowski, W.; Wyrwicz, L.; Wysocki, P. et al.
Source: Self-asserted source
Piotr Wysocki via Scopus - Elsevier

Polish clinical practice guidelines on Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cytoreductice Surgery (CRS) in peritoneal malignancy treatment,Zasady stosowania dootrzewnowej chemioterapii w hipertermii (HIPEC) w leczeniu nowotworów złosliwych powierzchni otrzewnej w połaczeniu z zabiegami cytoredukcyjnymi: zalecenia krajowe

Nowotwory
2014 | Journal article
EID:

2-s2.0-84920642889

Contributors: Rutkowski, P.; ͆piewankiewicz, B.; Herman, K.; Jastrzebski, T.; Kładny, J.; Kojs, Z.; Krzakowski, M.; Polkowski, W.; Wyrwicz, L.; Wysocki, P. et al.
Source: Self-asserted source
Piotr Wysocki via Scopus - Elsevier

Post-treatment surveillance in most common solid malignancies in adults,Badania kontrolne po leczeniu w najczestszych nowotworach litych u dorosłych

Nowotwory
2014 | Journal article
EID:

2-s2.0-84910092539

Contributors: Jassem, J.; Duchnowska, R.; Kawecki, A.; Krajewski, R.; Krzakowski, M.; Mądry, R.; Potemski, P.; Rutkowski, P.; Siebert, J.; Windak, A. et al.
Source: Self-asserted source
Piotr Wysocki via Scopus - Elsevier

Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: Independent validation of the p95HER2 clinical cutoff

Clinical Cancer Research
2014 | Journal article
EID:

2-s2.0-84901044363

Contributors: Duchnowska, R.; Sperinde, J.; Chenna, A.; Haddad, M.; Paquet, A.; Lie, Y.; Weidler, J.M.; Huang, W.; Winslow, J.; Jankowski, T. et al.
Source: Self-asserted source
Piotr Wysocki via Scopus - Elsevier

The Polish Task Force Position Statement on safety of biologic treatment with monoclonal antibodies and soluble receptors,Stanowisko Polskiej Grupy Ekspertow dotyczctce bezpieczehstwa leczenia przeciwcialami monoklonalnymi i bialkami fuzyjnymi

Polski Merkuriusz Lekarski
2014 | Journal article
EID:

2-s2.0-84907423882

Contributors: Jahnz-Rózyk, K.; Więsik-Szewczyk, E.; Filipowicz-Sosnowska, A.; Gil, J.; Grieb, P.; Jędrzejczak, W.W.; Owczarek, W.; Plusa, T.; Rutkowska-Sak, L.; Rydzewska, G. et al.
Source: Self-asserted source
Piotr Wysocki via Scopus - Elsevier

Cutaneous melanoma - Diagnostic and therapeutic guidelines in 2013,Czerniaki skóry - zasady poste{ogonek}powania diagnostyczno- terapeutycznego w 2013 roku

Przeglad Dermatologiczny
2013 | Journal article
EID:

2-s2.0-84875909982

Contributors: Rutkowski, P.; Wysocki, P.J.; Nowecki, Z.I.; Rudnicka, L.; Nasierowska-Guttmejer, A.; Fijuth, J.; Kalinka-Warzocha, E.; Świtaj, T.; Wojtukiewicz, M.; Zegarski, W. et al.
Source: Self-asserted source
Piotr Wysocki via Scopus - Elsevier
Items per page:
Page 1 of 3